Julie Theurer
Papers
6
Total Citations
652
H-Index
5
About
Dr. Julie Theurer is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the debate on optimal treatment for oropharyngeal squamous cell carcinoma (OPSCC). Her primary research areas center on comparing the efficacy and functional outcomes of radiotherapy (RT) versus transoral robotic surgery (TORS) for early-stage disease. Dr. Theurer is best known as a principal investigator of the landmark ORATOR trial, a phase II randomized study that provided the first high-level evidence directly comparing these two modalities. The trial’s initial results, published in 2019 and cited over 450 times, demonstrated comparable survival but significant differences in toxicity profiles, profoundly influencing clinical decision-making. Her subsequent work, including the final five-year outcomes published in 2024, continues to refine our understanding of treatment trade-offs. Beyond the trial, Dr. Theurer has been instrumental in developing TORS programs in Canada, addressing unique barriers to adopting advanced surgical technology. Her dedicated sub-studies on swallowing physiology provide critical, patient-centered data on functional preservation. With a cumulative citation count exceeding 650, Dr. Theurer’s rigorous, comparative research remains essential reading for any clinician or scientist navigating the complex landscape of oropharyngeal cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5Development of a transoral robotic surgery program in Canada5 citations · 2013
- 6